Pilot trial of OnabotulinumtoxinA (Botox) in moderate to severe restless legs syndrome

International Journal of Neuroscience

Volumn 121, Issue 11, 2011, Pages 622-625

  Agarwal, Pinky ^a   Sia, Cherri ^a   Vaish, Narendra ^b   Roy Faderman, Ina ^c  

^a Evergreen Hospital Medical Center   (United States)

^b Vaish Biotech Consulting   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Botulinum toxin; Clinical trials; Movement disorders; Restless legs syndrome; Sleep disorders

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; INTERNATIONAL RESTLESS LEGS SYNDROME SCALE; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT GLOBAL IMPRESSION CHANGE SCALE; PILOT STUDY; RATING SCALE; RESTLESS LEGS SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; PILOT PROJECTS; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; YOUNG ADULT;

EID: 80755142728     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.602774     Document Type: Article

References (10)

1. Brin Mitchell, F., Blitzer, A., Fahn, S., Gould, W., & Lovelace, R. E. (2004). Adductor laryngeal dystonia (spastic dysphonia): Treatment with local injections of botulinum toxin (Botox). Movement Disorders, 4, 287-296.
2. Epstein, R., Stygall, J., & Newman, S. (1997). The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia. Disability and Rehabilitation, 19, 20-25. (Pubitemid 27075682)
3. Ghorayeb, I., & Burbaud, P. (2009). Failure of botulinum toxin A to relieve restless legs syndrome. Sleep Medicine, 10, 394-395.
4. Hening, W. (2007). Current guidelines and standards of practice for restless legs syndrome. The American Journal of Medicine, 120, S22-S27. (Pubitemid 46014146)
5. Kushida, C. (2006). Botulinum toxin A: New hope for RLS? Journal of Clinical Sleep Medicine, 2, 279-280. (Pubitemid 44299550)
6. Nahab, F., Peckham, E., & Hallett, M. (2008). Double-blind, placebo-controlled, pilot trial of botulinum toxin type A in restless leg syndrome. Neurology, 71, 950-951.
7. Naumanna, M., Albaneseb, A., Heinenc, F., Molenaersd, G., & Reljae, M. (2006). Safety and effcacy of botulinum toxin type A following long-term use. European Journal of Neurology, 13, S35-S40.
8. Rotenberg, J., Canard, K., & DiFazio, M. (2006). Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A. Journal of Clinical Sleep Medicine, 2, 279-280.
9. Schapira, A. (2004). Restless legs syndrome: An update on treatment options. Drugs, 64, 149-158. (Pubitemid 38186963)
10. Tergau, F., Wischer, D., & Paulus, W. (1999). Motor system excitability in patients with restless legs syndrome. Neurology, 51, 1060-1063. (Pubitemid 29161620)